P. Dorff

发表

Solid phase synthesis of phosphinopeptoids as transition state analog inhibitors

B. Morgan, P. Dorff, Gordon Chiu, 1998 .

Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.

M. Mansour, J. Pandit, BinQing Wei, 2012, Journal of medicinal chemistry.

Application of Flow and Biocatalytic Transaminase Technology for the Synthesis of a 1-Oxa-8-azaspiro[4.5]decan-3-amine

Rajesh Kumar, P. Dorff, Chewah Lee, 2021 .

Novel solid-phase preparation of 2,6,9-trisubstituted purines for combinatorial library generation

R. Garigipati, P. Dorff, 2001 .

Investigation of the effects of synthetic, non-cytotoxic immunophilin inhibitors on MDR

S. Kajiji, P. Dorff, J. Dibrino, 1994 .

Deprotection of N-Boc Groups under Continuous-Flow High-Temperature Conditions.

Shu Yu, J. McWilliams, P. Dorff, 2019, The Journal of organic chemistry.

Potent small molecule CCR1 antagonists.

Christopher S. Poss, J. Kath, W. Brissette, 2004, Bioorganic & medicinal chemistry letters.

A solid phase CBZ chloride equivalent — a new matrix specific linker

P. Dorff, J. Hauske, 1995 .

3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents.

D. Rosi, E. Bacon, D. Young, 1993, Journal of medicinal chemistry.

Preparation and reactions of chiral propargylic amines

P. Dorff, G. Martinelli, J. Hauske, 1992 .

Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.

G. Y. Lesher, M. Reuman, M. Wentland, 1993, Journal of medicinal chemistry.

Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.

P. Pennock, M. Reuman, M. Saindane, 1995, Journal of medicinal chemistry.

Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.

M. Wentland, R. Perni, P. Dorff, 1988, Journal of medicinal chemistry.

Mammalian Topoisomerase II Inhibitory Activity of 1-Cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3 - quinolinecarboxylic Acid (I) and Related Derivatives.

Baldev Singh, G. Y. Lesher, M. Reuman, 1994 .

Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.

Gregory W. Kauffman, Chakrapani Subramanyam, L. Pustilnik, 2012, Journal of medicinal chemistry.

Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors.

L. Pustilnik, A. Stepan, R. Obach, 2011, Journal of medicinal chemistry.

Design and synthesis of novel FKBP inhibitors.

R. Williams, P. Dorff, J. Dibrino, 1992, Journal of medicinal chemistry.

Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's Disease.

Gregory W. Kauffman, L. Pustilnik, É. Hajós‐Korcsok, 2024, Journal of medicinal chemistry.